Arax Advisory Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Arax Advisory Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61K	Buy	28,634 +28,158	+5,916%	+$48.4K	﹤0.01%	3111
2026 Q1	$804	Buy	476 +469	+6,700%	+$2.06K	﹤0.01%	3341
2025 Q4	$36	Sell	7 -51,352	-100%	-$264K	﹤0.01%	3972
2025 Q3	$268K	Buy	+51,359	New	+$268K	﹤0.01%	1131
2025 Q2	–	Sell	-125	Closed	-$719	–	3035
2025 Q1	$719	Sell	125 -57	-31%	-$337	﹤0.01%	2433
2024 Q4	$909	Sell	182 -84	-32%	-$431	﹤0.01%	2196
2024 Q3	$1.43K	Hold	266	–	–	﹤0.01%	2149
2024 Q2	$881	Buy	+266	New	+$1.04K	﹤0.01%	2207

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Arax Advisory Partners's ALDX Position: Q2 2026 in Review

Arax Advisory Partners increased its Aldeyra Therapeutics (ALDX) stake by 5,916% in Q2 2026, buying an estimated $48.4K and bringing the position to 28,634 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #3111.

Arax Advisory Partners first reported a position in ALDX in Q2 2024 and has held it in 8 quarters since. The position peaked at $268K in Q3 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Arax Advisory Partners held 28,634 shares of Aldeyra Therapeutics worth $61K as of Q2 2026.
Arax Advisory Partners bought 28,158 Aldeyra Therapeutics shares in Q2 2026, an estimated $48.4K.
Aldeyra Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3111 holding.
Arax Advisory Partners first reported a position in Aldeyra Therapeutics in Q2 2024 and has held it in 8 quarters since.
Arax Advisory Partners's Aldeyra Therapeutics position peaked at $268K in Q3 2025.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.